Despite decades of progress, the majority of disease-relevant proteins remain undrugged. ChomiX combines chemoproteomic with covalent ligand discovery to systematically identify and validate novel binding sites, enabling a scalable path to first-in-class small-molecule therapeutics.
Our Science
We employ a chemoproteomics-enabled discovery engine, powered by covalent chemistry, to uncover novel binding sites across disease-relevant proteins. This platform has generated a broad set of biologically validated targets and selective small-molecule binders, establishing a strong foundation for the development of first-in-class therapeutic opportunities and a growing pipeline of programs.
Our Innovation Platform
Powering our approach is ChomiXScreen, our proprietary chemoproteomics platform, together with a curated library of covalent small molecules targeting reactive residues including cysteine, lysine, and serine. This integrated system enables unbiased, proteome-wide mapping of ligandable sites and supports small-molecule screening directly in live cells, including against targets traditionally considered undruggable. Continuous expansion of our chemical library and datasets drives pipeline growth and establishes a scalable foundation for first-in-class therapeutic discovery.
Platform Casestudy
